Aggressiveness of care in a prospective cohort of patients with advanced NSCLC

被引:86
|
作者
Temel, Jennifer S. [1 ]
McCannon, Jessica [2 ]
Greer, Joseph A. [3 ]
Jackson, Vicki A. [4 ]
Ostler, Patricia [1 ]
Pirl, William F. [5 ]
Lynch, Thomas J. [1 ]
Billings, J. Andrew [4 ]
机构
[1] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Dept Behav Med, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Palliat Care, Boston, MA 02114 USA
[5] Massachusetts Gen Hosp, Dept Psychiat Psychooncol, Boston, MA 02114 USA
关键词
end-of-life care; nonsmall-cell lung cancer; hospice care; chemotherapy;
D O I
10.1002/cncr.23620
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Optimal end of life care of patients with terminal cancer is poorly understood. In this study, the aggressiveness of care is described in a cohort of patients with newly diagnosed advanced nonsmall-cell lung cancer (NSCLC). METHODS. Patients within 8 weeks of diagnosis of stage IIIb (with effusions) or IV NSCLC were enrolled in a study to examine the feasibility of involving palliative care services early in the provision of cancer care. Participants received standard oncology treatment and integrated palliative care. All patients were followed prospectively to assess anticancer therapy usage, hospital admissions, hospice utilization, and location of death. RESULTS. At the time of analysis, 40/46 (87%) of enrolled patients had died, with a median length of follow-up of 29.3 months. Aggressive care measures in the final month of life included rates of anticancer therapy (40%), emergency department visits (48%), and hospital admissions (50%). Sixty-five percent of patients received hospice care before death, with a median length of stay of 16 days. Patients with heightened baseline anxiety and mood symptoms were more likely to receive anticancer therapy at the end of life compared with those without such symptoms. CONCLUSIONS. This study demonstrates the frequent use of aggressive measures at the end of life among patients with advanced NSCLC in a tertiary care center, as shown by the number of patients receiving anticancer therapy within 30 days of death and brief utilization of hospice services. further research is needed to identify predictors of aggressive care and to develop interventions enhancing decision-making at the end of life.
引用
收藏
页码:826 / 833
页数:8
相关论文
共 50 条
  • [21] Atezolizumab in Advanced NSCLC Patients with Baseline Brain Metastases: A Pooled Cohort Safety Analysis
    Lukas, Rimas
    Gandhi, Mayank
    O'Hear, Carol
    Hu, Sylvia
    Lai, Catherine
    Patel, Jyoti
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S941 - S942
  • [22] RECIST and iRECIST Comparison in a Cohort of Patients with Advanced NSCLC Treated with Immunotherapy: Preliminary Study
    Garcia Martinez, F.
    Fernandez-Velilla Pena, M.
    Cruz Castellanos, P.
    De Castro Carpeno, J.
    Pertejo, A.
    Torres Sanchez, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S980 - S980
  • [23] Pediatric Palliative Care Patients: A Prospective Multicenter Cohort Study
    Feudtner, Chris
    Kang, Tammy I.
    Hexem, Kari R.
    Friedrichsdorf, Stefan J.
    Osenga, Kaci
    Siden, Harold
    Friebert, Sarah E.
    Hays, Ross M.
    Dussel, Veronica
    Wolfe, Joanne
    PEDIATRICS, 2011, 127 (06) : 1094 - 1101
  • [24] Prospective cohort study of patients with advanced cancer and their relatives on the experienced quality of care and life (eQuiPe study): a study protocol
    van Roij, Janneke
    Zijlstra, Myrte
    Ham, Laurien
    Brom, Linda
    Fransen, Heidi
    Vreugdenhil, Art
    Raijmakers, Natasja
    van de Poll-Franse, Lonneke
    BMC PALLIATIVE CARE, 2020, 19 (01)
  • [25] Prospective cohort study of patients with advanced cancer and their relatives on the experienced quality of care and life (eQuiPe study): a study protocol
    Janneke van Roij
    Myrte Zijlstra
    Laurien Ham
    Linda Brom
    Heidi Fransen
    Art Vreugdenhil
    Natasja Raijmakers
    Lonneke van de Poll-Franse
    BMC Palliative Care, 19
  • [26] Hospice Care Improves Patients' Self-Decision Making and Reduces Aggressiveness of End-of-Life Care for Advanced Cancer Patients
    Wang, Chun-Li
    Lin, Chia-Yen
    Yang, Shun-Fa
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (23)
  • [27] A prospective validation of plasma ddPCR for rapid EGFR and KRAS genotyping of advanced NSCLC patients (pts).
    Sacher, Adrian G.
    Paweletz, Cloud
    Alden, Ryan
    O'Connell, Allison
    Mach, Stacy L.
    Janne, Pasi A.
    Oxnard, Geoffrey R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Bevacizumab Combined with Chemotherapy for Patients with Advanced NSCLC and Brain Metastasis. A French Cohort Study
    Bennouna, J.
    Falchero, L.
    Schott, R.
    Bonnetain, F.
    Coudert, M.
    Yahia, B. Ben Hadj
    Chouaid, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1808 - S1808
  • [29] EGFR mutations in patients with advanced NSCLC
    Fiala, Ondrej
    Pesek, Milos
    Finek, Jindrich
    Bruha, Frantisek
    Bortlicek, Zbynek
    Krejci, Jana
    Benesova, Lucie
    Minarik, Marek
    LUNG CANCER, 2012, 77 : S30 - S30
  • [30] ICIs for Elderly Patients with Advanced NSCLC
    Borghaei, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S147 - S147